✨ Free AI Report
Cardiff Oncology, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Cardiff Oncology, Inc.
Research Preview

Cardiff Oncology, Inc.: Business Overview, Financials & Competitive Analysis

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies. The company's lead asset, onvansertib, is in late-stage development for first-line RAS-mutated m...

Analyst-debate audio for Cardiff Oncology, Inc.

AskCyborg analysts argue the bull and bear cases for Cardiff Oncology, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Cardiff Oncology, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
7/ 10Strong

Cyborg Score thesis

PLK1 inhibition in first-line mCRC represents practice-changing potential with unmet medical need, supported by positive Phase 2...

Read the full analyst-debate transcript →
Industry Oncology Drugs
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Cardiff Oncology, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Cardiff Oncology, Inc. Overview

Pro stress-test →

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies. The company's lead asset, onvansertib, is in late-stage development for first-line RAS-mutated metastatic colorectal cancer (mCRC), a large underserved patient population with significant unmet medical need.

Strategic Profile

Pro stress-test →

Cardiff presented positive Phase 2 data at ASCO in June 2026, with the selected 30 mg onvansertib plus FOLFIRI/bevacizumab regimen demonstrating deep and durable tumor shrinkage with clinically meaningful improvements in confirmed ORR and PFS compared to standard of care alone, with no additive adverse events. The company completed a $10 million registered direct offering in August 2026 and plans to initiate a planned registrational trial in Q1 2027, subject to securing additional financing.

Competitive Landscape

Pro stress-test →

Cardiff operates in the oncology drug development space, competing with other companies developing colorectal cancer therapeutics. The competitive landscape includes established players developing novel approaches to RAS-mutated mCRC, though PLK1 inhibition represents a distinct mechanism of action. The company's focused pipeline on first-line mCRC with clear regulatory pathway creates a defined competitive position.

Industry Context

Cardiff Oncology, Inc. operates in Oncology Drugs.

Key facts

Headquarters: San Diego, US

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Cardiff Oncology, Inc..

+1 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Cardiff Oncology, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

BayerMultikinase inhibitor for colorectal cancer→Eli LillyBroad oncology portfolio including colorectal cancer treatments→RocheAnti-angiogenic therapy used in combination for mCRC→

Compare Cardiff Oncology, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Cardiff Oncology, Inc. operates in Oncology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Oncology Drugs research →
NEW · MCP server

Ask your AI assistant about Cardiff Oncology, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Cardiff Oncology, Inc. and its top competitor on Cyborg Score”
“What did Cardiff Oncology, Inc. do this quarter?”
“Is Cardiff Oncology, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Cardiff Oncology, Inc. do?+
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies. The company's lead asset, onvansertib, is in late-stage development for first-line RAS-mutated m...
What is Cardiff Oncology, Inc.'s Cyborg Score?+
Cardiff Oncology, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Cardiff Oncology, Inc.'s main competitors?+
Named competitors include Bayer, Eli Lilly, Roche. The full competitive landscape is in the AskCyborg report.
How can I get the full Cardiff Oncology, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Cardiff Oncology, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Cardiff Oncology, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Oncology Drugs research

Companies in the same sector and named competitors, ranked by Cyborg Score.

6Bayer AG8F. Hoffmann-La Roche AG